Madeleine is committed to supporting quality treatment and finding solutions to the opioid epidemic.
The opioid epidemic has exploded over the past few years—killing 70,000 people in America in 2018. Our nation is only just beginning to see the opioid epidemic for what it is: a disease that we must treat with robust funding for programs, research and education; punishment for the people and industries that profit from addiction; and compassion for those it afflicts.
As a member of the Freshman Working Group on Addiction, which works to bring bipartisan attention to the opioid epidemic, Madeleine has worked with her first-term colleagues to address the opioid epidemic crisis. Fighting for increases to the annual funding for the Substance Abuse and Mental Health Services Administration, programs for treatment for pregnant and postpartum women, and increasing access to medicated assisted treatment are just some of Madeleine’s work on this issue.
Additionally, Rep Dean has introduced H.R 4712, the Fairness in Orphan Drug Exclusivity Act, which would change existing statute that is preventing viable buprenorphine generics from coming to market – thereby ensuring future ease of access to one of the top medications used for Medically-Assisted Treatment (MAT). She has also introduced H.R. 7627, the MORE Savings Act which promotes affordable access to evidence-based opioid treatments under the Medicare program and requires coverage of MAT treatment for opioid use disorders.
